Provectus Biopharmaceuticals Inc PVCT:OTCQB

*Data is delayed | Exchange | USD
Last | 05/09/24 EDT
0.1959UNCH (UNCH)
52 week range
0.06 - 0.22
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.1959
  • 52 Week High0.22
  • 52 Week High Date03/18/24
  • 52 Week Low0.06
  • 52 Week Low Date10/18/23

Key Stats

  • Market Cap82.184M
  • Shares Out419.52M
  • 10 Day Average Volume144,873.6
  • Dividend-
  • Dividend Yield-
  • Beta0.74
  • YTD % Change104.06

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.1959
  • 52 Week High0.22
  • 52 Week High Date03/18/24
  • 52 Week Low0.06
  • 52 Week Low Date10/18/23
  • Market Cap82.184M
  • Shares Out419.52M
  • 10 Day Average Volume144,873.6
  • Dividend-
  • Dividend Yield-
  • Beta0.74
  • YTD % Change104.06

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-36.15
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-2.529M
  • ROE (TTM)-934.31%
  • Revenue (TTM)557,709.992
  • Gross Margin (TTM)-
  • Net Margin (TTM)-556.16%
  • Debt To Equity (MRQ)-38.89%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Provectus Biopharmaceuticals Inc

 

Profile

MORE
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade...
Edward Pershing CPA
Chairman of the Board, Chief Executive Officer
Dominic Rodrigues
President, Vice Chairman of the Board, Principal Executive Officer
Heather Raines CPA
Chief Financial Officer
Eric Wachter Ph.D.
Chief Technology Officer
Address
800 S. Gay Street, Suite 1610
Knoxville, TN
37929
United States

Top Peers

SYMBOLLASTCHG%CHG
RLMD
Relmada Therapeutics Inc
3.80-0.03-0.78%
CYTH
Cyclo Therapeutics Inc
1.45-0.05-3.33%
VYNE
Vyne Therapeutics Inc
2.65-0.07-2.57%
KALA
KALA BIO Inc
6.71-0.37-5.19%
DRRX
DURECT Corp
1.13+0.11+10.78%